Table 2.
Characteristics of included studies.
| Study | Country | Setting | N (total female) | N Bupropi on | N Compara tor | Mean age Bupropion | Mean age Comparat or | Intervention | Bupropion Dosage/day | Comparator | Comparat or Dosage/d ay | Duration | Depression |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Clayton 2004 [23] | US | Multicenter outpatient | 48 | 17 | 20 | 38.45 (5.73) | Bupropion SR | 300mg | Placebo | NA | 4 weeks | Yes | |
| DeFronzoDobkin 2006 [26] | US | Community & multicenter outpatient | 18 | NA | NR | NA | Bupropion SR | 150-300mg | NA | NA | 10 weeks | Yes | |
| Gitlin 2002 [29] | US | Community & multicenter outpatient | 15 | NA | 40.5 | NA | Bupropion SR | 100-300mg | NA | NA | 7 weeks | Yes | |
| Hartmann 2012 [25] | Germany | Outpatient from one center | 16 | NA | 40.3 | NA | Bupropion SR | 300mg | Placebo | NA | 16 weeks | No | |
| Kennedy 2006 [24] | Canada | Multicenter outpatient | 68 | 28 | 34 | 37.8 (10.5) | Bupropion SR | 150-300mg | Paroxetine | 20-40mg | 8 weeks | Yes | |
| Mathias 2006 [28] | Brazil | A private cancer center | 20 | NA | 50.6 (2.7) | NA | Bupropion | 75-150mg | NA | NA | 8 weeks | No | |
| Safarinejad 2011 [20] | Iran | Outpatient from one center | 218 | 109 | 109 | 33.7 (4.3) | 34.2 (4.1) | Bupropion SR | 150mg | Placebo | NA | 12 weeks | Yes |
| Safarinejad 2010 [21] | Iran | Outpatient from one center | 232 | 116 | 116 | 29.7 (5.2) | 29.2 (5.3) | Bupropion SR | 150mg | Placebo | NA | 12 weeks | No |
| Segraves 2001 [27] | USA | Multicenter outpatient | 55 | NA | 42 | NA | Bupropion SR | 300mg | NA | NA | 8 weeks | No | |
| Segraves 2004 [17] | USA | Multicenter outpatient | 66 | 31 | 35 | 36.1 | Bupropion SR | 150-400mg | Placebo | NA | 16 weeks | No | |
| Thase 2006 [22] | USA | Multicenter outpatient | 195 | 90 | 105 | 37.1 ± 12.3 | 37.4 ± 11.6 | Bupropion XL | 150-450mg | Venlafaxine XR | 75- 225mg | 12 weeks | Yes |
Legend: NA = Not available; SR = Slow Release.